-
i3 Announces Three Deals At 3rd Access To Markets Event
12 Dec 2025 18:11 GMT
… boost accountability.
Dr Ashifi Gogo, CEO and Founder of Sproxil, described … .”
The third announcement came from Boehringer Ingelheim’s Social Engagement Fund, which … Health, HELP Logistics, Sanofi, and Boehringer Ingelheim, i3 says A2M continues to …
-
Zealand pays Chinese OTR US$30m upfront to expand obesity pipeline
12 Dec 2025 10:28 GMT
… dual agonist in partnership with Boehringer Ingelheim. Zealand recently paused development of … Shanghai.
OTR’s founder and CEO Zhui Chen, Ph.D., described …
-
GRI Bio’s tazarotene achieves Phase IIa IPF success
11 Dec 2025 16:03 GMT
… 10 December statement, GRI Bio CEO Marc Hertz noted that the … -owned Genentech’s Esbriet and Boehringer Ingelheim’s Ofev being the last …
-
Zealand Bets Up To $2.5B in Metabolic Pact With Chinese Biotech
11 Dec 2025 14:12 GMT
… far back as 2011, when Boehringer Ingelheim took notice of survodutide (then … management for a new era,” CEO Adam Steensberg said in a …
-
i3 announces three major deals to accelerate African healthtech innovation
11 Dec 2025 10:36 GMT
… 10 percent.
Dr. Ashifi Gogo, CEO and Founder of Sproxil, hailed … . Gogo.
The event also saw Boehringer Ingelheim’s Social Engagement Fund announce … , Head of Sustainability Social at Boehringer Ingelheim, expressed her enthusiasm for the …
-
i3 Records 3 Groundbreaking Deals at 3rd Access to Markets Event
10 Dec 2025 22:17 GMT
… and NMEP, Dr. Ashifi Gogo, CEO and Founder of Sproxil said … families who need them most.”
Boehringer Ingelheim’s Social Engagement Fund celebrated … Health, HELP Logistics, Sanofi, and Boehringer Ingelheim.
Share 0
Post 0
Share …
-
i3 links African startups with global pharma in three major deals targeting cancer, malaria, pharmacy access
10 Dec 2025 16:26 GMT
… MSD with Kenya’s MYDAWA, Boehringer Ingelheim with three pharmacy-platform companies … and NMEP, Dr. Ashifi Gogo, CEO and founder of Sproxil said … families who need them most.”
Boehringer Ingelheim’s Social Engagement Fund celebrated …
-
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
10 Dec 2025 07:00 GMT
… said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. “T … partnerships including with Roche, Boehringer Ingelheim and Zymeworks as well … Partnering:
Dr Christian Rohlff, CEO
Partnering@oxfordbiotherapeutics.com Media:
MEDiSTRAVA …
-
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
09 Dec 2025 06:30 GMT
… of action. Marc Le Bozec, Chief Executive Officer at OSE Immunotherapeutics commented … EUR 17.5m payment from Boehringer Ingelheim, related to the 2024 acquisition …
-
Redefining clinical trials in oncology and rare diseases across the Europe
18 Nov 2025 19:42 GMT
… to companies such as Bayer, Boehringer Ingelheim, Heidelberg Pharma and Syneos Health … speech from Ivo Timmermans, co-chief executive officer at the Nijmegen, Netherlands …
About
© 1995-2025